Skip to main content

MIRA Pharmaceuticals, Inc.

corporate_fare Company Profile

MIRA Pharmaceuticals, Inc.

MIRA·NASDAQ·Life Sciences·CIK 0001904286

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on creating new oral medicines for neurological, neuropsychiatric, metabolic, and addiction-related conditions. The company has exclusive rights in the United States, Canada, and Mexico to three drug candidates: Ketamir-2, MIRA-55, and SKNY-1. These candidates are designed to address unmet medical needs in areas such as neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. Ketamir-2 is an oral NMDA receptor modulator that has completed a Phase 1 clinical trial in healthy volunteers, involving both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts. Preliminary safety data from this trial indicates no serious adverse events or dose-limiting toxicities, though the database is still blinded, and final analyses are ongoing. The company plans to start a Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026. MIRA-55 is a new oral, non-psychoactive cannabinoid analog currently in preclinical development for inflammatory pain and central nervous system conditions like anxiety and cognitive impairment. Preclinical studies have shown MIRA-55 has both pain-relieving and anti-inflammatory effects, comparable to morphine for pain relief, but without the central nervous system side effects seen with cannabinoids at tested doses. The company is moving MIRA-55 through IND-enabling development activities, aiming for an Investigational New Drug (IND) submission for inflammatory pain.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for MIRA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Ketamir-2 Results; DEA Confirms Not Controlled Substance
  • MIRA Pharmaceuticals Publishes Positive Preclinical Data for Obesity/Nicotine Drug SKNY-1
  • MIRA Pharmaceuticals Reports Going Concern Warning, Significant Losses, and Highly Dilutive Acquisition
  • Mira-55 Shows No CNS Side Effects in Preclinical Studies, Advancing IND Submission
  • MIRA Pharmaceuticals Completes Phase 1 Dosing for Ketamir-2 with Favorable Safety Profile

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$10.44M
Diluted EPS
-$1.35
Op. Cash Flow
-$4.66M
Cash & Equivalents
$6.35M
Debt / Equity
0.00×
Shares Outstanding
41.94M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014001
$0.297 +2.06% today
52-week range · as of 2026-11-16 $0.297 – $1.69
Market cap
$12.23M
Volume
570.1K (3.4× avg)
3-mo avg 167.8K
Live data · 2026-11-22 03:26 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MIRA - Filings & News (Page 2)

MIRA
May 13, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9747
Real-time Price: $0.297 info
Change: -$0.6777 (-70%) info
Market Cap: $12.228M info
MIRA
May 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.980
Real-time Price: $0.297 info
Change: -$0.683 (-70%) info
Market Cap: $12.228M info
MIRA
Mar 31, 2026, 2:02 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.07
Real-time Price: $0.297 info
Change: -$0.773 (-72%) info
Market Cap: $12.228M info
MIRA
Mar 23, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9785
Real-time Price: $0.297 info
Change: -$0.6815 (-70%) info
Market Cap: $12.228M info
MIRA
Mar 03, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.297 info
Change: -$0.943 (-76%) info
Market Cap: $12.228M info
MIRA
Feb 17, 2026, 8:30 PM EST
Filing Type: 5
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.297 info
Change: -$0.913 (-75%) info
Market Cap: $12.228M info
MIRA
Feb 02, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $0.297 info
Change: -$0.893 (-75%) info
Market Cap: $12.228M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets